-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

Benzinga·09/18/2026 16:39:10
Listen to the news
Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.